Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Gang, Zhou, Wenxuan, Li, Xiaoli, Guo, Lijie, He, Tingting, Zhao, Juan, Gong, Liansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/
https://www.ncbi.nlm.nih.gov/pubmed/34504494
http://dx.doi.org/10.3389/fimmu.2021.712351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/
https://www.ncbi.nlm.nih.gov/pubmed/34504494
http://dx.doi.org/10.3389/fimmu.2021.712351

Ejemplares similares